Company intelligence / Profile preview

Skyepharma

Saint Quentin Fallavier, Auvergne-Rhône-Alpes, Franceskyepharma.com ↗
Ownership
Private
Employees
~180
Development stage
Other
01

Overview

As a CDMO, clinical results pertain to client products manufactured or formulated using its technologies. The company has supported numerous approved drugs globally with its modified-release and complex oral dosage form expertise. Its facilities are FDA-, EU-, ANVISA-, and Korean MFDS-approved.

Therapeutic areas
PulmonologyCardiovascularNeurologyImmunology
Modalities
Small moleculeModified-release oral solid dosage forms
Industry
Contract Manufacturing Organization
02

Partnerships

SanofiMundipharmaKyorinNovartis

Beyond the preview

Go deeper on Skyepharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skyepharma.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call